Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vasopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 7/20 | 1.00 |
| ▸ | AVPR1B known ✓ | P47901 | 5/20 | 1.00 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 1.00 |
| ▸ | OXTR | P30559 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vasopressin SCHEMBL29688276 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL18937546 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL17874853 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.98 | AVPR1A (0.97) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL23879427 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL18476287 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL24390785 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL19733909 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL1172390 | 0.97 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL29500557 | 0.97 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577641-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| CN-119768510-A | Methods and compositions for producing hematopoietic endothelial cells from pluripotent stem cells | 特雷尔赫德生物系统股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| US-20240067932-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-02-29 | — | — | US | claimed |
| WO-2024044347-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-02-29 | — | — | WO | claimed |
| US-20250352512-A2 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-11-20 | — | — | US | disclosed |
| US-20250352513-A2 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-11-20 | — | — | US | disclosed |
| US-20250304893-A1 | PERFUSABLE 3D TUBULE-ON-CHIP MODEL DERIVED FROM KIDNEY ORGANOIDS WITH IMPROVED DRUG UPTAKE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250214934-A1 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-07-03 | — | — | US | disclosed |
| EP-4577641-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMOGENIC ENDOTHELIAL CELLS FROM PLURIPOTENT STEM CELLS | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250206701-A1 | C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-06-26 | — | — | US | disclosed |
| US-20250205197-A1 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-06-26 | — | — | US | disclosed |
| US-20250197351-A1 | C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11707447-B1 | C4-carbonothioate-substituted tryptamine derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2023-07-25 | — | — | US | disclosed |
| US-20220315574-A1 | Beta-Arrestin-Modulating Compounds and Methods of Using Same | UNIV DUKE (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3507299-B1 | IN-SITU SOLVENT RECYCLING PROCESS FOR SOLID PHASE PEPTIDE SYNTHESIS AT ELEVATED TEMPERATURES | CEM CORP (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-4007497-A2 | ß-ARRESTIN-MODULATING COMPOUNDS AND METHODS OF USING SAME | Duke University (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-11298367-B2 | Prodrugs of substituted triazole derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-12 | — | — | US | disclosed |
| EP-3257863-A1 | FLOUROUS METABOLICALLY STABLE PEPTIDE ANALOGS | Université de Strasbourg (FR) | 2017-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707447-B1 | C4-carbonothioate-substituted tryptamine derivatives and methods of using | HTR4, SLC6A4, HTR6 | AVPR1A 1104/4885AVPR1B 778/4885AVPR2 1363/4885 |
| US-20250352512-A2 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR4, HTR2C, HTR3C | AVPR1A 475/4885AVPR1B 392/4885AVPR2 504/4885 |
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | GLS, TNNI3, NAT1 | AVPR1A 1988/4885AVPR1B 1043/4885AVPR2 1052/4885 |
| US-20250214934-A1 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR4, HTR2C, HTR3C | AVPR1A 475/4885AVPR1B 392/4885AVPR2 504/4885 |
| US-20220315574-A1 | Beta-Arrestin-Modulating Compounds and Methods of Using Same | ARRB1, ADRB1, ADRB2 | AVPR1A 614/4885AVPR1B 282/4885AVPR2 623/4885 |
| US-20250205197-A1 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | SLC6A4, HTR2B, SLC6A3 | AVPR1A 231/4885AVPR1B 117/4885AVPR2 400/4885 |
| US-20250197351-A1 | C4-CARBOXYLIC ACID-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR2A, HTR1A, HTR3A | AVPR1A 101/4885AVPR1B 190/4885AVPR2 316/4885 |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | HTR6, TPH2, TPH1 | AVPR1A 209/4885AVPR1B 149/4885AVPR2 221/4885 |
| US-20250352513-A2 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | SLC6A4, HTR4, SLC6A3 | AVPR1A 451/4885AVPR1B 429/4885AVPR2 637/4885 |
| US-11298367-B2 | Prodrugs of substituted triazole derivatives and uses thereof | CYP4B1, AADAC, GLS | AVPR1A 2892/4885AVPR1B 2444/4885AVPR2 2259/4885 |
| US-20250206701-A1 | C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR4, SLC6A4, HTR6 | AVPR1A 1104/4885AVPR1B 778/4885AVPR2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.